On April 15, 2022, Jiangsu Baisaifei Biotechnology Co., Ltd. (hereinafter referred to as 'Baisaifei') officially announced the completion of Series B financing of over 100 million yuan. This round of financing was led by Huatai Zijin, an investment platform affiliated with strategic investor Huatai Securities. Old shareholder Jiuzhao Investment increased its equity investment, and Guoqian Venture Capital, Hongyuan Investment, Suzhou Industrial Park Science and Technology Innovation Fund and other institutions followed.
This round of financing will be mainly used to accelerate the continued layout of Bysaifei in the field of functional coating products for high-end medical devices, promote high-tech research and development and achievement transformation in the field of IVD and high-end biological consumables, improve the regulatory scientific research and inspection and testing service levels of functional coating medical devices, and support the construction of a production base in Suyu Biomedical Industrial Park in Changshu.
Construction plan of Shusuyu production base
'I am very grateful to Huatai and other new shareholders for their recognition of Baisaifei, as well as the continued support of old shareholder Jiuzhao,' Professor Chen Hong, founder of Baisaifei, said, 'The reason why Biosurf is favored by investors and people from all walks of life is that we are engaged in a very meaningful cause and have a team with super strong combat effectiveness. In the past five years, Biosurf has focused on the blue ocean market of medical device functional coatings, broke through the key technical bottlenecks in this field, and successfully developed a series of medical functional coating materials, equipment and quality evaluation methods and technologies with independent intellectual property rights and international advanced levels, providing many domestic Foreign medical device companies have provided coating products and technical services, which have greatly promoted domestic medical device companies to achieve product upgrades and launch innovative products. At the same time, they have also rapidly increased the brand influence of Biosurf in the medical coating industry. In the future, we will continue to adhere to the striver-oriented value concept, give full play to the team's underlying technology research and development advantages, continuously enhance the digital enterprise management system, and strive to build an international biomaterial surface modification technology platform to better serve healthy life.'
Dr. Chen Miao, co-head of Huatai Zijin Health Fund, said: 'Besaifei is one of the few biomaterial surface and interface modification technology platform companies in China. The team members with founder Professor Chen Hong as the core have been deeply involved in biomaterial surface and interface modification technology for many years, and have established an industry-leading biomaterial surface and interface technology system and comprehensive R&D service platform. The company's technology has successfully realized the commercial application and import substitution of a variety of products in the field of medical devices, filling many domestic gaps and providing complete solutions to better meet clinical needs. At the same time, the company's technology has also shown great development potential in other life and health-related industries.'
Mr. Shen Hongli, founding partner of Jiuzhao Investment , said: 'Jiu Zhao Investment has always paid attention to leaders in various innovation fields, with special attention to the independent research and development and domestic substitution of core medical materials. Based on its founder, Professor Chen Hong's long-term academic accumulation in this field, Baisaifei has successfully realized technology transformation and has grown into a leading enterprise in the domestic medical coating field. Jiu Zhao Investment Capital has been with Baisaifei since its establishment and will continue to support Baisaifei's outstanding development in the future. We believe that Baisaifei will continue to lead the industrial development in the field of biomaterial surface modification technology and become an internationally competitive track with its outstanding original innovation capabilities and core technology reserves.'
Dr. Zhang Xu, founder of Guoqian Venture Capital , said: 'GuoqianR is honored to be a partner of Besaifei. The upgrading of China's domestic medical devices and import substitution are the general trend. Medical functional coatings are an important technical means to improve the performance of medical devices, especially mid-to-high-end implantable interventional medical devices. Medical functional coating platform technology meets strong clinical needs, high technical barriers, and a large market Characteristics of volume. The Baisaifei team has more than 20 years of R&D experience in the field of surface and interface modification of biomaterials, and its R&D strength is at the forefront of the industry. Through the cross-integration of biology, chemistry, materials, mechanical automation and other disciplines, it can solve the needs of the entire industry chain of medical coatings in one stop. It is a rare team in the industry that can promote the establishment of industry standards.
Mr. Gao Hongbing, executive director of Hongyuan Investment, said: 'Medical functional coatings are key raw materials necessary for implantable and interventional medical devices. They have long relied on imports. In the context of increasing risks in the international supply chain and price reductions in centralized procurement of consumables, there is an urgent need for independent research and development and domestic substitution. With its profound accumulation of basic research and strong technological development strength, the Baisaifei team has broken through key bottlenecks in this field and realized the industrialization of the entire chain of medical-based functional coatings. It has been highly recognized by many customers and is worthy of long-term optimism. '
Mr. Chen Lian, deputy general manager of Suzhou Industrial Park Science and Technology Innovation Fund Manager Leading Venture Capital, said: 'I am honored to be able to cooperate with the team of Baisaifei. Over the years, the Baisaifei team has continuously invested in research and development in the stuck field of medical functional coatings. It has a deep accumulation of cutting-edge technology research and development and a technology transformation team with high execution capabilities. The products have been widely recognized by the market. We are optimistic about the market opportunities for domestic substitution of upstream core materials and components for medical consumables. We believe that the company will continue to consolidate the layout of the entire industrial chain of medical coatings, further develop innovative products, and become an international leader in the field of medical coatings.'
Based on the founder's more than 20 years of professional accumulation in the field of biomaterial surface interfaces and domestic and foreign academic influence, Jiangsu Baisaifei Biotechnology Co., Ltd. focuses on innovative research and development of biomaterial surface modification technology and the development of high-end functional coating products with independent intellectual property rights and international competitiveness. Since its establishment in 2017, the company has created a domestic professional technical service platform covering the entire industry chain of medical functional coatings with a complete set of surface coating technology solutions for implantable medical devices with high technical thresholds. It has broken foreign technology monopoly, filled many domestic gaps, and successfully achieved import substitution. According to public data from the State Intellectual Property Office, Bysaifei has become the company with the most applications and authorized patents in China in the global medical coating industry, and has participated in a number of coating projects. The regulatory scientific research related to medical devices and the establishment of product quality standards have formed a comprehensive technical service and innovative product platform with biomaterial surface modification technology as the core, integrating the research and development and production of coating materials, advanced manufacturing of coating equipment, coating process development and foundry, coating quality analysis instrument development and inspection services, and the development of new coating products. It aims to create an internationally leading brand of independent and controllable biofunctional coatings and related products, and promote the high-quality development of the health industry. Based on the founder's more than 20 years of professional accumulation in the field of biomaterial surface interfaces and domestic and foreign academic influence, Jiangsu Baisaifei Biotechnology Co., Ltd. focuses on innovative research and development of biomaterial surface modification technology and the development of high-end functional coating products with independent intellectual property rights and international competitiveness. Since its establishment in 2017, the company has created a domestic professional technical service platform covering the entire industry chain of medical functional coatings with a complete set of surface coating technology solutions for implantable medical devices with high technical thresholds. It has broken foreign technology monopoly, filled many domestic gaps, and successfully achieved import substitution. According to public data from the State Intellectual Property Office, Bysaifei has become the company with the most applications and authorized patents in China in the global medical coating industry, and has participated in multiple coatings Medical device-related regulatory scientific research and the establishment of product quality standards have formed a comprehensive technical service and innovative product platform with biomaterial surface modification technology as the core, integrating the research and development and production of coating materials, advanced manufacturing of coating equipment, coating process development and foundry, coating quality analysis instrument development and inspection and testing services, and the research and development of new coating products, creating an internationally leading brand of independent and controllable biofunctional coatings and related products, and promoting the high-quality development of the health industry。
Huatai Zijin is a wholly-owned subsidiary of Huatai Securities (601688.SH) engaged in private equity investment business. Relying on the advantages of Huatai Securities' full business chain, adhering to the investment philosophy of 'growing together with entrepreneurs', and relying on its rich financial and industrial resources, it provides partners with a full range of capital services. The company has a registered capital of 6 billion yuan and a management scale of over 50 billion yuan. It owns multiple funds such as PE, M&A, FOF, and industry. Huatai Zijin adheres to industry positioning and is based on solid industry research. It has deeply cultivated strategic emerging industries such as medical health and TMT, and has accumulated rich industry experience and resources. At the same time, it has given full play to the capital operation advantages of the securities dealer system, and its investment has promoted many companies to successfully enter the A/H share market. It has also provided all-round support around industry leaders, forming industry-leading industrial investment and M&A capabilities. Huatai Zijin's investment portfolio in the medical and health industry includes: Mindray Medical (300760), WuXi AppTec (603259.SH/2359.HK), Rongchang Biologics (09995.HK), Gene Biotech (603387), and Borui Pharmaceuticals (688166), Aidi Pharmaceutical (688488), Shuo Shi Biotech (688399), Shuyu Mining (301017), Pumen Technology (688389), Xintong Medical (2160.HK), Novozymes (688105), etc. Huatai Zijin is a wholly-owned subsidiary of Huatai Securities (601688.SH) engaged in private equity investment business. Relying on the advantages of Huatai Securities' full business chain, adhering to the investment philosophy of 'growing together with entrepreneurs', and relying on its rich financial and industrial resources, it provides partners with a full range of capital services. The company has a registered capital of 6 billion yuan and a management scale of over 50 billion yuan. It owns multiple funds such as PE, M&A, FOF, and industry. Huatai Zijin adheres to industry positioning and based on solid industry research, deeply explores strategic emerging industries such as medical and health care, TMT, etc., and has accumulated rich industry experience and resources. At the same time, it fully leverages the capital operation advantages of the securities dealer system, and its investment has promoted the successful entry of many companies into the A/H share market. It also provides all-round support around industry leaders, forming industry-leading industrial investment and M&A capabilities. Huatai Zijin's investment portfolio in the medical and health industry includes: Mindray Medical (300760), WuXi AppTec (603259.SH/2359.HK), Rongchang Biologics (09995.HK), Gene Biotech (603387), and Borui Pharmaceuticals (688166), Aidi Pharmaceutical (688488), Shuoshi Biotech (688399), Shuyu Mining (301017), Pumen Technology (688389), Xintong Medical (2160.HK), Novozymes (688105), etc.
Jiuzhao Investment focuses on investing in strategic emerging industries vigorously developed by the country, focusing on exploring and investing in high-quality projects in the fields of biomedicine and health, high-end equipment manufacturing, artificial intelligence and big data, new energy and new materials, and new generation information technology. It adheres to the development concept of 'empowering technology with investment and benefiting mankind with technology' and adopts the investment strategy of 'high-quality products + empowerment + heavy positions'. It screens high-quality investment projects in the early stage, and subsequently provides professional and comprehensive housekeeping services to invested companies to carry out in-depth empowerment. Jiuzhao Investment is headquartered in Beijing and has branches in Nanjing, Shenzhen, Guangzhou, Shanghai, Chengdu, Dalian, Xi'an and other places. Its investments include Tianzhihang (688277.SH), Nanjing Tiansu, Baiwang, Huiqiang New Materials, Jiutian MSI, Corestar, Holy Point Technology, Leju Robot, Galaxy Water Drop, Jingye Bearing, Weihe Biotech, Yuannian Technology and other industry unicorns or specialized new enterprises.。
Hongyuan Investment started engaging in equity investment business in 2005 and is one of the first 12 registered venture capital institutions in Shanghai. Through its own and entrusted management funds, the company carries out a full-stage layout of project incubation, early-stage venture capital investment and mid- and late-stage equity investment. It has discovered and empowered enterprise founders and teams, and has made a cumulative external investment of more than 2 billion yuan. More than ten of the invested companies have been successfully listed, including Minova Pharmaceuticals, Borui Pharmaceuticals, Aipeng Medical, etc.
◎The copyright of this work belongs to Baisaifei. If you need to reprint it, please contact me.
